本頁面由Tiger Trade Technology Pte. Ltd.提供服務

BioLine Rx

2.93
+0.01000.34%
盤後2.930.00000.00%16:10 EST
成交量:2,367.00
成交額:7,101.09
市值:1,274.95萬
市盈率:-2.26
高:3.16
開:3.03
低:2.91
收:2.92
52周最高:7.77
52周最低:2.30
股本:435.14萬
流通股本:417.35萬
量比:0.17
換手率:0.06%
股息:- -
股息率:- -
每股收益(TTM):-1.2972
每股收益(LYR):-4.6176
淨資產收益率:-21.24%
總資產收益率:-13.60%
市淨率:0.65
市盈率(LYR):-0.63

資料載入中...

2021/01/19

[補充]招股説明書

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2021/01/11

SEC問詢函

CORRESP [Cover] - Correspondence
2021/01/06

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/11/23

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/11/03

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/07/01

SEC問詢函

CORRESP [Cover] - Correspondence
2020/06/26

招股説明書

F-1 - Registration statement for certain foreign private issuers
2020/06/05

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/06/05

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/06/05

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/06/02

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/05/26

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/05/20

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/12

年度報告

Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/03/12

財報披露

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/05

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/02/27

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/02/14

超過5%披露

Statement of acquisition of beneficial ownership by individuals
2020/02/07

超過5%披露

[Amend] Statement of acquisition of beneficial ownership by individuals
2020/01/30

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]